Rationale for Combination Angiotensin Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor Treatment and End-Organ Protection in Patients with Chronic Kidney Disease

Chronic kidney disease (CKD) is a major public health problem that has received increasing attention because of the high rate of associated cardiovascular morbidity and mortality. Mounting evidence indicates that angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) safely slow down progression of CKD. There is also growing evidence supporting...